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Abstract: Inhibition of amyloid fibril formation could benefit patients with systemic amyloidosis. In
this group of diseases, deposition of amyloid fibrils derived from normally soluble proteins leads to
progressive tissue damage and organ failure. Amyloid formation is a complex process, where several
individual steps could be targeted. Several small molecules have been proposed as inhibitors of
amyloid formation. However, the exact mechanism of action for a molecule is often not known, which
impedes medicinal chemistry efforts to develop more potent molecules. Furthermore, commonly
used assays are prone to artifacts that must be controlled for. Here, potential mechanisms by which
small molecules could inhibit aggregation of immunoglobulin light-chain dimers, the precursor
proteins for amyloid light-chain (AL) amyloidosis, are studied in assays that recapitulate different
aspects of amyloidogenesis in vitro. One molecule reduced unfolding-coupled proteolysis of light
chains, but no molecules inhibited aggregation of light chains or disrupted pre-formed amyloid
fibrils. This work demonstrates the challenges associated with drug development for amyloidosis,
but also highlights the potential to combine therapies that target different aspects of amyloidosis.
Keywords: systemic amyloidosis; amyloid fibrils; amyloidogenesis inhibitors; antibody light chains;
light-chain stabilizers; doxycycline; EGCG; thioflavin T; filter trap; PAINS
1. Introduction
Deposition of amyloid fibrils derived from antibody light-chain (LC) proteins is asso-
ciated with organ damage in the disease amyloid light-chain (AL) amyloidosis [1,2]. AL
amyloidosis is the most commonly diagnosed form of “systemic” amyloidosis, where
amyloid fibrils form in multiple tissues [3]. In these diseases, amyloid fibrils are closely
associated with pathology, and inhibition of amyloid deposition by suppression or stabiliza-
tion of the precursor protein can lead to clinical benefits [4]. Here, “amyloidosis” refers to
the disease and “amyloidogenesis” refers to the biochemical process of amyloid formation
from soluble precursor proteins. “AL” is often used as a shorthand for AL amyloidosis,
but strictly refers to the amyloid protein in its fibrillar state [3].
In AL amyloidosis, the precursor LCs are secreted from a clonal population of B
lymphocytes, most often plasma cells in the bone marrow [1]. Amyloid fibrils are formed
from a single “monoclonal” LC with a sequence that is unique to each patient. LCs are
~215-residue proteins that form two structural immunoglobulin domains. The N-terminal
variable (VL) domain, which forms the structured core of AL amyloid fibrils, is the location
of most of the diversity between LCs. The C-terminal constant (CL) domain is much more
conserved and has a scaffolding and chaperone function. LCs can form homodimers, which
may be stabilized by an inter-chain disulfide bond between the CL-domains.
Preventing amyloid deposition in AL amyloidosis is a longstanding goal of research
and treatment. Cytotoxic chemotherapy can kill the clonal plasma cells, thus reducing
levels of monoclonal LCs below that necessary for aggregation [5]. However, many patients
are diagnosed after the onset of organ failure, which complicates treatment [6]. Therefore,
substantial efforts are devoted to developing therapeutic strategies that could benefit these
patients [7].
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Amyloidogenesis by folded proteins is a complex, multi-step process (Figure 1),
and pharmacologic intervention at any of these points could potentially benefit patients.
Importantly, these steps could be targeted in combination, which could potentially lead to
synergy between approaches. Several small molecules have been suggested as potential
therapies for different amyloid diseases. Given the high cost of drug development, most
research has focused on natural products or existing drugs. These molecules potentially
offer a starting point for medicinal chemistry approaches to develop more efficacious
molecules. Despite promising reports of efficacy in in vitro assays of amyloidogenesis, or
even in clinical trials, intense lead optimization has not generally been carried out. One
reason for this lack of optimization is the complexity of amyloidogenesis. It has been
difficult to determine exactly which step or steps are affected by a particular molecule, and
their precise molecular targets are not known.
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of the native LC are defined as kfold and kunfold, respectively. The self-assembly process is divided into initiation and elon-
gation steps, with rate constants k1on/off and k2on/off, respectively. Proteolysis is irreversible with a rate constant of kp, and 
leads to self-assembly of fragments with rate constants k1′on/off. LCs can form multiple fibril structures. Therapies for AL 
amyloidosis (blue text and arrows) could potentially target any of these steps, which implies that combining therapies 
with different mechanisms of action could benefit patients. Existing treatments aim to kill the clonal cells that secrete the 
LCs. Alternative treatments could suppress formation of non-native amyloidogenic LC species (stabilizers), inhibit 
self-association (amyloidogenesis inhibitors), or promote the dissolution or removal of existing amyloid fibrils (amyloid 
dissociators). 
Other than eradication of the producer cells, there are several potential mechanisms 
by which a drug could benefit individuals with AL amyloidosis. One strategy is to sup-
press unfolding of the protein and thereby reduce the levels of amyloid-competent spe-
cies. This approach has been clinically efficacious in transthyretin amyloidosis, where the 
“kinetic stabilizer” drug tafamidis is approved in multiple regions [8,9]. Several mole-
cules have been proposed as stabilizers of LCs [10–12] and we are actively pursuing this 
strategy. Alternatively, a drug could interfere with the self-association of non-native 
amyloid precursors to suppress self-association and amyloid formation. This approach 
has been explicitly pursued for several proteins, including α-synuclein [13] and insulin 
[14], and is proposed as a mechanism of action of other molecules. A similar approach is 
the capping of pre-existing amyloid fibrils to prevent their extension [15]. A third group 
of potential therapies aims to dissociate preexisting amyloid fibrils, either via small 
molecules, antibodies, or a combination of the two. Monoclonal antibodies directed at 
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inhibit self-association (amyloidogenesis inhibitors), or promote the dissolution or removal of existing amyloid fibrils
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Other than eradication of the producer cells, there are several potential mechanisms by
which a drug could benefit individuals with AL amyloidosis. One strategy is to suppress
unfolding of the protein and thereby reduce the levels of amyloid-competent species. This
approach has been clinically efficacious in transthyretin amyloidosis, where the “kinetic
stabilizer” drug tafamidis is approved in multiple regions [8,9]. Several molecules have
been proposed as stabilizers of LCs [10–12] and we are actively pursui g this strategy.
Alternatively, a drug could int rfer with the self-association of n n-n tive amyloid recur-
sors to suppress self-association and amyloid formation. This approach has been explicitly
pursued for several proteins, including α-synuclein [13] and ins lin [14], and is prop sed a
a mechanism of action of other m lecules. A similar approach is the capping of pre-existing
amyloid fibrils to prevent their extension [15]. A third group of potential therapies aims to
dissociate preexisting amyloid fi rils, either via small mole ules, antibodies, or a ombi-
nation of the two. Monoclonal antibodies directed at either the fibrils themselves [16,17]
or the accessory protein serum amyloid P component (SAP) [18,19] have been used in
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clinical trials to recruit phagocytic cells to clear the amyloid. These strategies are outlined
in Table 1.
Table 1. Potential strategies to inhibit LC amyloidogenesis. Note that the mechanisms of action of
doxycycline and epigallocatechin gallate (EGCG) are not known.
Strategy Examples Comments
Cytotoxic agents




In routine clinical use. Suppress
LC secretion by killing the
producer cells. Significant
side-effects.
Native state stabilizers Coumarin 1Methylene Blue












Clinical trials in progress.
Limited efficacy observed to
date, possibly due to diverse
fibril structures.
In a typical drug development effort, high-throughput screening is used to identify
molecules with activity in one or more assays, and counter-screening is used to remove
the inevitable false-positive hit molecules. Counter-screening is critically important when
introducing new molecules to an assay, because of the possibility for unexpected interac-
tions between the small molecule and the system. “Pan-assay interference compounds”
(PAINS) have been identified as recurrently problematic in multiple assays [20], and many
molecules can also interfere with assays by forming colloidal aggregates [21]. Once a
molecule has been identified as a true-positive hit, chemical analogs are synthesized with
the aim of improving the efficacy of the molecule in assays, or optimizing other desirable
properties. Anti-amyloidogenic activity in vitro is likely a necessary property for a poten-
tial drug for amyloidosis, but this activity must also be maintained in vivo. A candidate
drug must also be sufficiently bioavailable and non-toxic at the concentrations required
for activity in humans. Each of these properties can potentially be optimized, but this
optimization is challenging without detailed information about a molecule’s target and
mechanism of action.
The action of drug-like small molecules on amyloidogenesis is often assessed by
their ability to prevent amyloid formation in vitro. However, molecules could in principle
act anywhere along the reaction pathway depicted in Figure 1. More problematically,
experimental artifacts could occur at any point along this pathway. Observations that
certain molecules, such as doxycycline, appear to inhibit the aggregation of multiple
proteins [22–24] may imply the existence of common protein structures that represent a
general molecular target for amyloidosis. Similarly, reports that diverse small molecules
can inhibit amyloidogenesis of proteins with immunoglobulin folds (including LCs and
β2-microglobulin) may indicate that for each protein, there are multiple potential tar-
get structures [10,12,23,25]. However, these observations could also represent recurring
experimental artifacts in multiple systems.
This work aims to identify the mechanisms by which small molecules could inhibit
amyloidogenesis of antibody LCs. We have previously used high-throughput screening
to identify small molecules that stabilize native LCs [10]. Here, a “drug repurposing”
approach was investigated, using molecules that have been extensively studied in other
amyloid systems. Eight small molecules, which have been suggested to inhibit some
aspect of amyloidogenesis in either LCs or other amyloid precursor proteins, were tested
in a series of simple assays designed to probe different potential mechanisms of action.
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The goals were to ask whether previous results could be recapitulated in experimental
systems established in our laboratory, and if so, to determine the relevant mechanism of
action. Identifying such a mechanism of action could allow a small molecule’s effects to be
optimized via medicinal chemistry and identify molecules with complementary activities.
A further goal was to test whether these molecules have a sufficiently large, true-positive
effect that they would be selected and validated in a high-throughput screen.
2. Results
In order for LCs to form amyloid fibrils, productive interactions must occur between
rare, transiently populated LC structural species. The steady-state concentration of these
species is defined by both the rate of LC secretion from plasma cells and the stability of the
LC, which is its propensity to remain in its folded state. Post-translational modifications
may alter these processes. Most clearly, proteolytic cleavage of LCs can lead to fragments
which are more amyloidogenic [26,27]. Full-length LCs are more stable in vitro and less
prone to aggregation under native-like conditions than their component VL-domains [26,28].
AL fibrils appear to be primarily composed of fragments of LCs, although the nature of this
cleavage is unknown and may happen after deposition as amyloid [27,29–33]. The nascent
amyloid fibrils must be stable enough to recruit new protein molecules and grow into
mature fibrils, rather than dissociate. These fibrils deposit in tissues and form interactions
with other molecules, such as components of the extracellular matrix and SAP, which
further stabilizes them. Finally, fibrils must be resistant to clearance by cells including
macrophages that would normally remove macroscopic debris. The fine details of how
these processes play out in an individual patient likely depend on the unique sequence of
the monoclonal LC.
Other than eradication of the producer cells, there are several potential mechanisms by
which a drug might inhibit amyloidogenesis. Since self-assembly of LCs requires multiple
steps which cannot be easily resolved, the approach here was to look for large effects on
amyloidogenesis using simple assays, which could then potentially be resolved further.
LCs derived from the IGLV6-57 gene, which is over-represented in AL amyloidosis, were
studied. Three mechanisms are investigated: stabilization of the full-length LC native state,
inhibition of VL-domain self-assembly, and dissolution of pre-formed VL-domain amyloid
fibrils. The differences between these mechanisms can be visualized using a simplified free
energy diagram (Figure 2), which makes two key assumptions. Amyloid is assumed to be
the most stable state at equilibrium, and only a single transition state, corresponding to
self-assembly of non-native species, is assumed to be rate-limiting. This transition state
model is an approximation of the multiple transition states that would be necessary to
fully describe amyloidogenesis. The equilibrium stability of amyloid relative to soluble
LCs is defined as ∆Gfibril, which depends on concentration. The limit of solubility, or
critical concentration, is defined as the total concentration of LC where ∆Gfibril is zero.
Each potential inhibitory mechanism represents the interaction of a small molecule with
a single LC conformational state. This interaction alters the relative free energy of that
state, leading to distinct consequences. Stabilization of the native state would lead to a
decrease in the rate of aggregation and a decrease in the equilibrium concentration of
amyloid. Inhibition of self-association would also decrease the rate of aggregation, but
would not alter the equilibrium concentration of amyloid. Dissolution or destabilization of
amyloid fibrils would reduce the equilibrium concentration of amyloid but not alter the
rate at which it is formed. These energetic properties mean that it should be possible to
distinguish how small molecules alter amyloidogenesis using a kinetic assay that detects
amyloid fibrils, such as measuring the fluorescence of thioflavin T (ThT), a benzothiazole
dye with environment-sensitive fluorescence properties whose fluorescence increases when
bound to amyloid fibrils. However, if amyloid is substantially more stable than native
LCs, even a large free energy change in the presence of a small molecule may not lead
to a measurable change in the amount of amyloid present at equilibrium. Measuring the
amounts of soluble and insoluble LC, both at the endpoints of the aggregation reaction and
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following incubation of pre-formed fibrils with small molecules, allows these mechanisms
to be distinguished more readily. Deviations from this model would indicate more complex
mechanisms of aggregation or of small molecule action.
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Eight molecules were studied (Figure 3): (1) Coumarin 1, which was identified as
a stabilizer of native LCs [10]. (2) Doxycycline, a tetracycline antibiotic, which has been
proposed to inhibit amyloid formation by several proteins, including LCs, and disrupt
amyloid fibrils [22–24,34]. (3) Oxidized and (4) reduced forms of epigallocatec in gallate
(EGCG), which have been proposed to rem del amyloid fibrils [35,36] and have be n used
in clinical trials for AL amyloidosis [37]. EGCGox and EGCGred refer to pre-oxidized and
freshly thawed EGCG, respectively. (5) Rifampicin and (6) rifamycin SV, two relat d ant bi-
otics, which have been shown in v tro to interfere with self-ass ciation of β2-microglobulin,
an amyloid-forming protein with a CL-domain-like secondary structure [25]. (7) Methylene
blue, wh ch has been shown to inhibit formation of amyloid fibrils by tau [38] nd LCs [12].
(8) Diflunisal, a stabilizer of the native state of tranthyretin [39,40] i not expected to interact
with LCs and was included as a negative control. LCs derived from the IGLV6-57 gene,
wh ch is over-represented in AL amyloidosis [41], are us d in all experiments. For each
exp riment, a different LC was used in order to maximize the signal that was measured,
as described belo . In all experiments, LC concentration was 5 µM (monomer equivalent;
0.06 mg/m VL-domain or 0.12 mg/mL full-length LC) and small molecule concentration
was 50 µM. All experiments were carried out in phosphate-buffered saline (PBS) at pH
7.4 and 37 ◦C. Doxycycline, EGCG, and methylene blue are soluble in water at the stock
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concentration of 5 mM, and other molecules were dissolved in ethanol. To verify that the
ethanol had no influence on the LCs, additional controls using 1% (v/v) ethanol vehicle
were used in each experiment.
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2.1. Native State Stabilization
Amyloid fibrils are non-native assemblies, so unfolding from the LC native state,
during or after secretion, is required for a yloid formation. The rate at which LCs unfold
to form non-native species is described by their kinetic stability, which describes the e ergy
barrier to unfolding [26]. Limited proteolysis [42] is a method to measure kinetic stability
in a disease-relevant manner, since proteolysis appears to be important for AL amyloidosis
pathogenesis. Non-native LC conformations are more susceptible to endoproteolysis than
native LCs because endoproteases preferentially bind to unstructured peptide substrates.
Since proteolysis is irreversible and faster than refolding, the rate at which a folded pro-
tein is degraded is determined by its unfolding rate, a situation known as EX1 kinetics
(Figure 4a). Stabilization was assessed using an unstable full-length LC derived from a
patient with AL, known as WIL [43], which we previously showed could be stabilized
by small molecules [10]. Using this unstable LC maximizes the potential signal of the
experiment, which is defined by the extent to which unliganded LCs are degraded over the
incubation period. This approach of measuring at a single timepoint to infer the kinetics of
a well-defined system is a way to minimize the number of measurements required for an
experiment, which is important for high-throughput screening.
LCs were incubated with proteinase K, a highly active protease that cleaves after
aliphatic residues. Using this protease allows for detection of transient unfolding of regions
of LCs that may lack cleavage sites for a less promiscuous protease. Three replicates were
measured. After 4 h of incubation at 37 ◦C, reactions were quenched with a covalent
protease inhibitor and residual full-length LCs were measured by SDS-PAGE. The extent of
degradation of LCs in the presence or absence of small molecules is shown in Figure 4b. Of
the molecules tested, only coumarin 1 consistently protected the LC against proteolysis.
This observation is in agreement with the results of a previous high-throughput screen,
where we verified that coumarin 1 binds directly to LCs and does not inhibit proteinase
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K [10]. The degradation of LCs in the presence of other small molecules supports the
hypothesis that these molecules do not act by binding to the LC native state.




Figure 4. Stabilization of LCs measured by proteolysis. (a) Experimental outline. Transient unfolding of native LCs (N) to 
protease-sensitive conformations (U) limits the rate at which the LCs are cleaved by proteinase K. Binding of 
small-molecule ligands (M) stabilizes LCs against unfolding and therefore reduces the rate of proteolysis. (b) Residual 
full-length LC after incubation with proteinase K and small molecules was measured by SDS-PAGE (n = 3 independent 
reactions per molecule). Top, example gel showing the starting material (left lane) and remaining LC after incubation 
(right lanes). Bottom, quantitation of gel bands, relative to the un-proteolyzed LC. 
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protease inhibitor and residual full-length LCs were measured by SDS-PAGE. The extent 
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Figure 4. Stabilization of LCs easured by proteolysis. (a) Experi ental outline. Transient unfolding of native LCs ( ) to
protease-sensitive conformations (U) limits the rate at which the LCs are cleaved by proteinase K. Binding of small-molecule
ligands (M) stabilizes LCs against unfolding and therefore reduces the rate of proteolysis. (b) Residual full-length LC
after incubation with proteinase K and small molecules was measured by SDS-PAGE (n = 3 independent reactions per
molecule). Top, example gel showing the starting material (left lane) and remaining LC after incubation (right lanes).
Bottom, quantitation of gel bands, relative to the un-proteolyzed LC.
2.2. Inhibition of Amyloidogenesis
A potential drug for amyloidosis could specifically inhibit self-association of amyloid-
competent species, affecting early initiation steps, subsequent elongation of fibrils, or both
processes (k1on, k1′on, or k2on in Figure 1). Successful inhibition of any of these processes
would lead to a reduction in the rate of amyloidogenesis (Figure 2), which could then
be followed up with further experiments. For LCs, this self-association occurs between
non-native structural conformations that either exist in equilibrium with the native state
or can be formed following proteolysis. Several potential mechanisms by which such
inhibition could occur are described in Figure 5. These mechanisms all involve binding
of small molecules to transiently populated LC species, increasing the energy barrier
to amyloidogenesis. Since these mechanisms would not alter the free energy difference
between the native and fibrillar LC (Figure 2), there would be no reduction in the endpoint
fraction of amyloid fibrils. However, the rate at which amyloid is formed would be reduced,
possibly to the extent that no fibrils are formed over the course of an experiment.
Rational design of molecules that inhibit protein self-association is difficult because
the properties of the protein species that self-assemble are not known, and these species
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Molecules that extend the lag phase may be more likely to be true-positive hits than those
that reduce the final fluorescence intensity of the aggregate-bound ThT.
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Rational design of molecules that inhibit protein self-association is difficult because 
the properties of the protein species that self-assemble are not known, and these species 
are only transiently present in solution, often at very low concentration. Furthermore, 
designing inhibitors of specific protein–protein interfaces is challenging because these 
interfaces often comprise multiple weak, non-specific interactions. Efforts to identify in-
hibitors of amyloidogenesis therefore often rely on screening libraries of compounds 
with assays that detect amyloid fibril formation, such as fluorescence of ThT. Molecules 
that cause a reduction in ThT fluorescence after incubation with aggregation proteins 
would be considered hits. However, these assays are prone to false positives because 
displacement of ThT from fibrils or quenching of fluorescence could be interpreted as 
inhibition of amyloid formation (Figure 5c). Furthermore, the emission of fibril-bound 
ThT is not well-understood and can differ between batches of fibrils. Aggregation often 
proceeds with “sigmoidal” kinetics, where a “lag” phase is followed by a rapid increase 
in ThT fluorescence, which is a result of a reduced energy barrier to fibril extension 
(Figure 2b). Molecules that extend the lag phase may be more likely to be true-positive 
hits than those that reduce the final fluorescence intensity of the aggregate-bound ThT. 
A number of molecules have been proposed to alter the morphology of the aggre-
gates formed in vitro. However, whether these structural transformations are accessible 
to amyloid fibrils in patients is not known. If amyloid fibrils are highly stable under 
physiological conditions and LC concentrations, interconversion between alternate ag-
gregate conformations is likely to be slow. This can be visualized by large energy barriers 
between different aggregate conformations (Figure 5a), corresponding to discrete fibril 
conformations that are only accessible via soluble, unfolded LCs. Non-fibrillar assem-
blies, which are often called “amorphous aggregates”, may be less stable and more ac-
cessible at equilibrium, and some small molecules appear to be able to direct protein ag-
gregation towards such assemblies. Moreover, the mechanisms by which amyloid fibrils 
cause tissue damage are poorly understood, so it is not clear whether species such as 
amorphous aggregates, “spherical oligomers,” or “protofibrils” actually represent a less 
toxic endpoint than amyloid. These structures may be an additional source of variability 
in ThT experiments, since ThT may bind to different structures with different affinity. 
Due to these potential artifacts, the results of a ThT-binding experiment should therefore 
be verified by measuring a property such as residual soluble protein. 
To ask whether small molecules can inhibit amyloidogenesis, their effect on LC 
VL-domain aggregation was measured in vitro by ThT kinetics (Figure 6). The LC 
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accessible to the LCs, shown as distinct energy minima. However, the energy barriers to interconversion between these states
are likely to be large, requiring dissociation, unfolding, and reaggregation of the subunit molecules. (b) Small molecules
could inhibit amyloid formation (or enhance amyloid dissociation) via multiple mechanisms, depicted schematically.
(c) Amyloid formation can be readily measured by binding of the fluorogenic dye thioflavin T (shown as a cyan bar), but
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A number of molecules have been proposed to alter the morphology of the aggregates
formed in vitro. However, whether these structural transformations are accessible to amy-
loid fibrils in patients is not known. If amyloid fibrils are highly stable under physiological
conditions and LC concentrations, interconversion between alternate aggregate conforma-
tions is likely to be slow. This can be visualized by large energy barriers between different
aggregate conformations (Figure 5a), corresponding to discrete fibril conformations that
are only accessible via soluble, unfolded LCs. Non-fibrillar assemblies, which are often
called “amorphous aggregates”, may be less stable and more accessible at equilibrium,
and some small molecules appear to be able to direct protein aggregation towards such
assemblies. Moreover, the mechanisms by which amyloid fibrils cause tissue damage are
poorly understood, so it is not clear whether species such as amorphous aggregates, “spher-
ical oligomers,” or “protofibrils” actually represent a less toxic endpoint than amyloid.
These structures may be an additional source of variability in ThT experiments, since ThT
may bind to different structures with different affinity. Due to these potential artifacts, the
results of a ThT-binding experiment should therefore be verified by measuring a property
such as residual soluble protein.
To ask whether small molecules can inhibit amyloidogenesis, their effect on LC VL-
domain aggregation was measured in vitro by ThT kinetics (Figure 6). The LC VL-domain
used is known as JTO-VL, which was originally identified in an individual with multiple
myeloma, and which reproducibly forms amyloid fibrils in vitro [26,43]. Full-length LCs
derived from the IGLV6-57 gene, including JTO, do not readily aggregate at neutral pH,
but their isolated VL-domains do so [26]. JTO-VL is not derived from a patient with
amyloidosis, but it aggregates readily and is predominantly folded under the conditions
used for aggregation [26,44]. JTO-VL reproducibly aggregates with kinetics that can be
fitted to mechanistic models, but the kinetics are sensitive to reaction conditions and there
is some variability in the ThT fluorescence measurements, particularly in the endpoint
fluorescence intensity [26]. To minimize the effects of such variability, aggregation reactions
were carried out in parallel on the same microwell plate. Although microplate-based
methods yield less well-resolved data than cuvette-based measurements, they allow side-
by-side comparison of multiple small molecules, using replicates to quantify ri ilit .
Full-length JTO was used as a negative contr l, because this LC does not form ThT-binding
aggregates under simil conditions [26,45].
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sign is shown at the top. After 24 h of aggregation monitored by ThT fluorescence, the effect of 
Figure 6. Aggregation of LC VL-domains measured by thioflavin T fluorescence. Experimental
design is shown at the top. After 24 h of aggregation monitored by ThT fluorescence, the effect of
small-molecule addition to pre-formed fibrils on ThT fluorescence was measured (Figure 7, below),
and the amount of soluble and aggregated LC is quantitated by the filter trap assay (Figure 8, below).
Orange traces represent fluorescence intensity changes (n = 3 wells) in the presence of small molecules,
and grey traces represent control wells where small molecules were added after 24 h (n = 3 wells).
Panels on the right show the detail of the time period where aggregation occurs.
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At the endpoint of the aggregation reactions, the presence of soluble and insoluble 
LC aggregates was assessed by a “filter trap” differential membrane binding assay [46] 
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aggregates, then a cellulose nitrate membrane, which binds soluble protein. Protein 
binding to each membrane is measured by staining with amido black dye [47]. The ratio 
igure 7. The effect of addition of small molecules to pre-form d, ThT-bound fibrils. Fibril formation
was monitored by ThT fluorescence as described in Figure 6. The decrease in ThT fluorescence
shown for rifampicin, rifamycin SV, and methylene blue is consistent with fluorescence quenching or
displacement of ThT from fibrils.
In the absence of small molecules, JTO-VL reproducibly forms ThT-binding aggregates
after 8–12 of i cubation with continuous shaking (Figure 6). Five mol cul s—oxidized
and reduc d EGCG, rifampicin, rifam cin SV, and methylene blu —all suppress the rise in
ThT fluorescence associated with amyloiodgenesis. Coumarin 1 increases the fluorescence
signal before the initiation of aggregation, due to its own fluorescence. However, closer
examination of the kinetic traces (Figure 6, right panels) reveals an increase in ThT fluores-
cence at a similar ti e to that observed in the absence of small molecules. These results
appear to be consistent with the hypothesis that the small molecules destabilize or remodel
amyloid fibrils, leading to less ThT-binding material at the end of the reaction (Figure 2).
To test whether these molecules disrupt the binding or fluorescence of ThT, additional
samples of JTO-VL in adjacent wells were allowed to aggregate for 24 h (grey curves in
Figure 6), after which small molecules were added. The change in ThT fluorescence upon
addition of rifamycin SV, rifampicin, and methylene blue is consistent with suppression of
ThT fluorescence, rather than inhibition of aggregation (Figure 7).
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samples (top) show the staining of soluble or aggregated LCs on cellulose acetate or cellulose nitrate membranes. Two types
of soluble LCs were used as negative controls for aggregation: JTO-VL that had not been incubated at 37 ◦C and full-length
JTO that did not aggregate over the course of the experiment. Note that several small molecules, especially methylene blue,
stain the membranes in the absence of protein, which affects their apparent quantitation. (c) Aggregate load is estimated
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At he endpoin of the aggregation reacti ns, the presence of soluble and insolubl
LC aggregates was assessed by a “filter trap” differential membrane binding assay [46]
(Figure 8). Samples are drawn through a cellulose acetate membrane, which traps large
aggregates, then a cellulose nitrate membrane, which binds soluble protein. Protein
binding to each membrane is measured by staining with amido black dye [47]. The
ratio between the staining intensity of the two membranes can report on the relative
solubility of the LC. Molecules which suppress aggregation would be expected to reduce
the amount of insoluble protein and retain soluble protein. Following aggregation, staining
of soluble LCs decreased substantially compared to the non-aggregated controls, while
staining of insoluble LCs increased, consistent with the presence of aggregates. Several
molecules, particularly methylene blue, are colored, and cause visible staining on one or
both membranes, making quantitation less accurate. Despite this limitation, aggregated
LC species are present in all samples (Figure 8b). There is little apparent loss of cellulose
acetate membrane staining that would correspond to insoluble material in the presence
of small molecules. Similarly, there is no increase in cellulose nitrate membrane staining
indicative of increased levels of soluble LC. Notably, similar levels of aggregate are detected
in both the wells where small molecules were added before aggregation (Figure 8c, orange
symbols), and those where small molecules were added to pre-formed fibrils (Figure 8c,
grey symbols). LC aggregates which formed in the presence of EGCG stained more
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intensely with amido black than other aggregates, which may indicate differences in
aggregate morphology, consistent with the weak binding of these aggregates to ThT.
These data indicate that none of the small molecules tested prevent LC VL-domain
aggregation under these conditions. It is possible that non-amyloid aggregates are formed,
which do not bind to ThT, but soluble protein is not retained in solution.
2.3. Dissolution of Pre-Formed Amyloid Fibrils
A small molecule that destabilizes amyloid fibrils and enhances their dissolution
could help to clear fibril deposits from patients. This potential mechanism of action is
distinct from inhibition of LC self-association, since the molecular target of the small
molecule is the fibrils rather than pre-fibrillar intermediates. However, a sufficiently large
effect could be observed in a ThT kinetic experiment as a reduction in the endpoint ThT
fluorescence (Figure 2). Although small molecules including EGCG and doxycycline have
been proposed to “remodel” existing fibrils, the mechanism by which this could occur is not
clear. Above the critical solubility concentration, amyloid fibrils are more stable than their
soluble precursors (Figure 2). Molecules that preferentially bind to amyloid fibrils over
native LCs would enhance the stability of the fibrils, the opposite of the intended effect.
Any destabilization of amyloid could occur via interactions with unfolded species that
are present at equilibrium. Protein subunits continually exchange between the fibrils and
solution, so a molecule that stabilizes non-fibrillar conformations could lead to dissociation
of amyloid, potentially favoring the formation of non-amyloid, “amorphous” aggregates.
However, such interactions would also necessarily occur during amyloidogenesis, diverting
protein molecules away from fibril-competent conformations and altering the observed
reaction kinetics. Therefore, a small molecule that destabilizes fibrils would likely affect
the results of a ThT kinetics experiment.
Although the mechanisms involved have not been characterized, dissociation or
alteration of pre-formed amyloid fibrils has been observed in the presence of small
molecules [22,24]. Therefore, the effect of small molecules on the solubility of LC VL-
domain amyloid fibrils, which were formed in vitro before addition of small molecules, was
tested. LC VL-domain amyloid fibrils from a relatively stable VL-domain, the “germline”
IGLV6-57 sequence, referred to as 6aJL2-VL [48], were used to maximize the likelihood
that any LC that dissociated from the fibril would remain folded in solution. Amyloid
dissolution is likely to occur slowly because of the large free energy barrier to dissociation
(Figure 2). Doxycycline has been reported to dissociate amyloid fibrils over a 15-day time
period [22]. Therefore, duplicate fibril samples were incubated with small molecules for 7
and 15 days.
After 7 and 15 days of incubation at 37 ◦C, LC solubility was assessed by the filter
trap assay (Figure 9). To maximize the detection of soluble or insoluble material, LCs
were precipitated by centrifugation, and the supernatant and resuspended precipitate were
analyzed separately for each time point (orange and blue symbols in Figure 9, respectively).
A single sample of soluble LC was used as a positive control. Staining of membranes
by small molecules impeded quantitation of solubility, as described above. Quantitation
of total aggregate staining shows that samples incubated with small molecules do not
have reduced levels of insoluble LC (Figure 9c). The proportion of aggregated LC can be
inferred from the ratio of cellulose acetate staining to cellulose nitrate staining (Figure 9d),
which shows no difference between samples incubated with or without any small molecule
except for methylene blue. However, methylene blue preferentially stains cellulose nitrate
(Figure 8), so this observation does not necessarily demonstrate dissociation of aggregates.
Furthermore, apparent levels of aggregated LC were higher in the precipitate fraction of all
samples, consistent with retention of aggregated LC. Overall, no sample showed evidence
of reduced aggregate content following incubation.




Figure 9. Dissociation of pre-formed amyloid fibrils measured by the filter trap assay. (a) Experi-
mental outline. Pre-formed fibrils (n = 2 samples per condition) were incubated with small mole-
cules for 7 or 15 days, after which bulk aggregated LCs were precipitated by centrifugation. The 
soluble and insoluble LC in the supernatant (sn, orange) and precipitate (ppt, blue) were measured 
by the filter trap assay. (b) Example membranes showing aggregated (cellulose acetate membrane 
stain) and soluble (cellulose nitrate membrane stain) LC in the supernatant and precipitate of one 
set of samples incubated for 7 days. (c) Total aggregate levels in each sample, relative to the 
most-stained membrane region. (d) Ratio of aggregated to soluble LC after 7 days (hollow symbols) 
or 15 days (solid symbols). The reduced apparent aggregation observed in the presence of meth-
ylene blue appears to be due to staining of the cellulose nitrate membrane by the small molecule. 
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Figure 9. Dissociation of pre-formed amyloid fibrils easured by the filte trap assay. (a) Experimental outlin . Pre-formed
fibrils (n = 2 samples per condition) were incubated with small molecules for 7 or 15 days, after hich bulk aggregated LCs
were precipitated by centrifugation. The soluble and insoluble LC in the supernatant (sn, orange) and precipitate (ppt, blue)
were measured by the filter trap assay. (b) Example membranes showing aggregated (cellulose acetate membrane stain) and
soluble (cellulose nitrate membrane stain) LC in the supernatant and precipitate of one set of samples incubated for 7 days.
(c) Total aggregate levels in each sample, relative to the most-stained membrane region. (d) Ratio of aggregated to soluble
LC after 7 days (hollow symbols) or 15 days (solid symbols). The reduced apparent aggregation observed in the presence of
methylene blue appears to be due to staining of the cellulose nitrate membrane by the small molecule. Symbols are colored
as for panel (c).
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3. Discussion
Inhibition of amyloid fibril formation is challenging, and it is perhaps surprising that
so many small molecules have been reported to inhibit the amyloidogenesis of several
proteins in vitro or have shown efficacy in clinical trials. Such observations with natural
products or drugs approved for other indications raise the possibility that more efficacious
inhibitors of amyloidogenesis could be developed. As a first step towards this goal,
this study attempted to identify molecules that could inhibit amyloidogenesis of LCs,
and the mechanisms by which these molecules did so. Table 2 summarizes the results
of these experiments. In these model systems, no molecule led to suppression of LC
aggregation, although five small molecules suppressed ThT fluorescence. These molecules—
oxidized and reduced EGCG, methylene blue, rifampicin, and rifamycin SV—reduced the
amplitude of the endpoint ThT fluorescence. In a typical high-throughput assay where
only endpoint fluorescence was measured, these molecules would all have registered as
hits. However, none of these molecules suppressed total aggregation, and three, methylene
blue, rifampicin, and rifamycin SV, appeared to alter the fluorescence of ThT, possibly
by displacing or quenching ThT fluorescence. These results highlight the importance
of verifying the effects of small molecules on ThT aggregation experiments, using an
orthogonal assay.
Table 2. Summary of results. Values represent mean ± standard deviation, n = 3 replicates. EGCGox and EGCGred refer to












Fibrils after 15 Days
(Filter Trap)
Coumarin 1 0.88 ± 0.13 0.97 ± 0.12 No No
Doxycycline 0.28 ± 0.037 0.94 ± 0.18 No No
Diflunisal 0.47 ± 0.085 0.75 ± 0.08 No No
EGCGox 0.29 ± 0.025 0.25 ± 0.01 No No
EGCGred 0.4 ± 0.17 0.23 ± 0.02 No No
Rifampicin 0.49 ± 0.4 0.42 ± 0.03 No No
Rifamycin SV 0.25 ± 0.025 0.41 ± 0.11 No No
Methylene blue 0.3 ± 0.057 0.41 ± 0.02 No No
Since AL amyloid is derived from a LC protein that is normally folded, stabilization of
the LC native state presents an additional opportunity for intervention, analogous to that
used successfully for transthyretin amyloidosis [8,9]. Coumarin 1, which was previously
identified as a stabilizer of LCs [10], was able to protect a full-length, unstable LC from
unfolding and subsequent proteolysis (Figure 3). If the hypothesis that unfolding of LCs
from their native state is required for aggregation is correct, molecules that stabilize LCs in
a similar way to coumarin 1 could reduce aggregation and benefit patients. Importantly,
although coumarin 1 is active in this assay, it has a relatively weak affinity for LCs, around
3 µM for full-length WIL, and is unlikely to be sufficiently potent to be active in vivo.
Therefore, the weaker protection afforded by doxycycline (Figure 3) likely does not explain
the activity of doxycycline in patients [49,50]. The details of how coumarin 1 and other hits
from the screen bind to LCs have been identified [10,11], and this information has been
used to design and synthesize new molecules which are more efficacious stabilizers of
LCs [51].
The ability of small molecules to suppress amyloidogenesis or disrupt amyloid fibrils
in vitro has supported ongoing clinical trials of doxycycline and EGCG for individuals with
systemic amyloidosis. However, both molecules are pleiotropic and are known to affect
multiple processes in vitro and in vivo. Clearer mechanistic data on how these molecules
work could help to optimize their eventual clinical use.
Doxycycline is a widely prescribed tetracycline antibiotic, which has been shown to pre-
vent amyloidogenesis and disrupt amyloid fibrils formed by several proteins in vitro [22–24].
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Doxycycline reduced LC-associated toxicity in a nematode model [52]. Doxycycline also
suppressed amyloid deposition in a mouse model of AL amyloidosis and inhibited amyloid
formation, but not aggregation, of a full-length LC derived from the IGKV1-33 gene [24].
The experimental conditions used to induce aggregation of this full-length LC included
cycles of 4 h incubations at 65 ◦C [24], which may lead to different aggregate structures
than the conditions used in the experiments described in Figures 6–8. Doxycycline was
also observed to alter the morphology of fibrils extracted from an individual with AL
amyloidosis [24]. These observations are consistent with data presented in Figures 8 and 9
because alternative aggregate species would still be detected in the filter trap assays.
Clinical studies have shown a beneficial effect of using doxycycline over other antibi-
otics in patients with AL amyloidosis [49,50,53]. However, the effects of doxycycline on
amyloidogenesis in vitro have been most thoroughly characterized for β2-microglobulin.
Although the clinical effects are generally described as being due to doxycycline’s ability
to disrupt amyloid fibrils, doxycycline could affect many aspects of amyloid formation
or patient metabolism. For example, tetracyclines are inhibitors of translation [54] and
of matrix metalloproteinases [55], which may both contribute to efficacy. Alternatively,
doxycycline could simply be an effective antibiotic in patients with amyloidosis, which is
potentially important since treatments directed at antibody-secreting cells can have severe
immunosuppressive side effects.
Many small molecules show activity in vitro at micromolar concentrations, but it is not
clear that such activity can be extrapolated to patients, where drug absorption and plasma
protein binding can significantly reduce the effective concentration of the small molecule,
even if toxicity is not limiting. A small, uncontrolled clinical trial suggested improvements
in patients [56] with β2-microglobulin amyloidosis, even though the plasma concentration
of doxycycline in these individuals was only around 2 µM. Doxycycline reduces the rate of
aggregation of an amyloidogenic variant of β2-microglobulin, as measured by both ThT
fluorescence and solubility measurements [34]. However, in these studies, doxycycline
inhibited amyloidogenesis of 20 µM β2-microglobulin only at concentrations of 50 µM
or greater.
The data presented here are not consistent with doxycycline being an inhibitor of LC
amyloidogenesis in vitro. Overall, these data support a mechanism of action for doxycy-
cline in AL amyloidosis that does not depend entirely on its ability to prevent amyloidoge-
nesis or disrupt fibrils. Thus, doxycycline may complement both existing cytotoxic agents
and novel, non-cytotoxic therapies in patients.
Another molecule that has been studied in detail is EGCG, a bioactive compound
found in green tea. Biochemical studies show that EGCG can modulate protein aggregates,
in some cases “remodeling” fibrils to form other oligomeric species [35,36]. However, a
Phase 2 trial of EGCG in AL amyloidosis failed to show a significant benefit [37] and two
other trials (NCT01511263 and NCT02015312) have not reported results.
Small molecules can interfere with biochemical or cell-based assays in multiple ways.
Several classes of molecules are regarded as “pan-assay interference” compounds, or
PAINS. EGCG is a well-known example: catechols can form reactive orthoquinones upon
oxidation [35]. However, pre-oxidation of EGCG did not alter its activity in these assays.
Methylene blue, rifamycin SV, and rifampicin all appear to reduce the fluorescence of
amyloid-bound ThT. Each of these molecules is colored in solution, a property that should
be noted as a potential complication in any optical assay.
The major limitation of this study is that only single examples of LCs were used in each
assay. The effects of individual molecules could be unique to specific LC sequences studied.
Notably, the study which identified methylene blue as a stabilizer of LCs investigated its
binding to the VL-domain of a LC derived from the IGLV2-8 gene [12]. However, the IGLV6-
57 LC gene used in these experiments is over-represented in AL amyloidosis compared
to the normal repertoire [41]. The morphologies of the aggregates formed in the presence
of small molecules was not investigated further because the physiological relevance of
different aggregate structures is not known. Non-amyloid LC aggregates are associated
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with organ toxicity in light-chain deposition disease and multiple myeloma [57,58]. Another
limitation is that only a single concentration of small molecule was used in each experiment.
Dose–response studies are critical to differentiating between small molecules. However,
on-target activity was only observed for coumarin 1, for which dose–response data have
been published [10].
Treatment of AL amyloidosis has benefited enormously from improvements in cyto-
toxic drugs directed against clonal plasma cells over the last three decades [1]. Further
improvements in patient care may be possible by augmenting this strategy with drugs that
target different aspects of the disease pathology.
4. Materials and Methods
Small molecules were purchased from Sigma (St. Louis, MS, USA) or Thermo Fisher
(USA), and 5 mM stocks in water (doxycycline hyclate, EGCG, methylene blue) or ethanol
(coumarin 1, diflunisal, rifamycin SV, rifampicin) were prepared and stored at −20 ◦C until
needed. “Oxidized” EGCG was prepared by incubating aliquots of EGCG overnight at
37 ◦C in water, which were then stored at −20 ◦C. All experiments were carried out in
phosphate-buffered saline (PBS; 1.5 mM KH2PO4, 8.1 mM Na2HPO4, 2.7 mM KCl, 138 mM
NaCl, pH 7.4) at 37 ◦C.
Data were analyzed and figures prepared using the “Tidyverse” [59] suite of tools
for R [60], within the RStudio environment [61]. Final figures were prepared using
Adobe Acrobat.
4.1. Light-Chain Preparation
Light chains were cloned into vectors containing T7 promoters and recombinantly ex-
pressed in BL21 (DE3) E. coli, as previously described [26]. Full-length LCs were expressed
as inclusion bodies in the E. coli cytosol. Cells were lysed by sonication and insoluble
material was washed three times with PBS containing 1% NP-40 detergent, then once with
PBS. Inclusion bodies were resuspended in 25 mM Tris-Cl, pH 8 (room temperature pH
value), containing 4 M guanidine hydrochloride and 5 mM dithiothreitol for at least 2 h, at
4 ◦C, before being refolded by dropwise dilution into 25 mM Tris-Cl pH 8 on ice to dilute
out the denaturant. VL-domains were expressed in the E. coli periplasm and extracted by
periplasmic shock. Cell pellets were resuspended in 200 mM tris pH 8 containing 0.5 M
sucrose and 5 mM EDTA, incubated on ice for 30 min, then shocked by addition of two
volumes of deionized water. Cells were removed by centrifugation. Both full-length LCs
and VL-domains were concentrated by ammonium sulfate fractionation (LCs precipitate in
the 25–75% saturation fraction at 4 ◦C), resuspended in 25 mM Tris-Cl, pH 8, and dialyzed
against 25 mM Tris-Cl, pH 8, to remove residual ammonium sulfate. LCs were purified by
ion exchange and size exclusion chromatography on Source 15Q and Superdex 75 columns
(Cytiva, Marlborough, MA, USA). LCs were eluted from the size exclusion column in PBS,
aliquoted, snap-frozen, and stored at −80 ◦C.
4.2. Limited Proteolysis
LCs (5 µM) were incubated at 37 ◦C for 4 h in the presence of small molecules (50 µM)
or appropriate vehicle control, with or without 200 nM proteinase K (Thermo Fisher).
Reactions were initiated by adding 2 µL proteinase K or buffer to 18 µL LC solution
and incubated in a thermocycler with a heated lid to minimize evaporation. At the
end of the incubation time, reactions were quenched with 2 µL of 10 mM phenylmethyl
sulfonyl fluoride, which rapidly and irreversibly inactivates the protease. The extent of
proteolysis was measured by SDS-PAGE. Loading buffer was added to each sample to a
final concentration of 2% SDS, 10% glycerol, and 0.1% 2-mercaptoethanol, and the samples
were incubated at 98 ◦C for 6 min. Samples were run on 16% tris-glycine polyacrylamide
gels (Thermo Fisher), stained with GelCode Blue (Thermo Fisher), and visualized using
an ImageQuant LAS 4000 gel imaging system (Cytiva). Bands were quantitated with
ImageLab software (Bio-Rad, Hercules, CA, USA). Remaining LC was defined as the
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intensity of the full-length LC band after proteolysis, relative to the un-proteolyzed LC
sample, calculated independently for each of three gels.
4.3. Amyloidogenesis Kinetics
Thioflavin T (Sigma) was dissolved in ethanol, diluted in PBS to approximately
200 µM, then filtered to remove aggregates. Filtration of ThT often leads to some loss of
dye, so ThT concentration was determined by spectroscopy (extinction coefficient of 28,000
at 414 nm) after filtration. Aggregation was carried out in black, clear-bottomed polystyrene
microwell plates (item #3631, Corning Life Sciences, Glendale, AZ, USA). JTO-VL was
thawed and filtered through a 0.22 µm syringe filter, then added to pre-filtered ThT at
final concentrations of 5 µM LC and 5 µM ThT in PBS. The outer wells of the plate were
filled with 200 µL PBS to help stabilize the temperature and humidity within the sealed
plate and thereby minimize evaporation, leaving 60 wells for LC samples. To each of these
wells, 99 µL of LC and ThT solution was added, followed by 1 µL of the appropriate small
molecule or vehicle. Small molecule was added to 3 wells per molecule before aggregation,
and a further 3 wells were used as controls, where the small molecule was added after
aggregation to assess the effect of the molecule on ThT fluorescence. Plates were sealed
with film, then covered with a lid that was held in place by adhesive tape. Fluorescence
(λex = 440 nm, λem = 480 nm, reading through the bottom of the plate) was measured in
a SpectraMax M5 plate-reader (Molecular Devices, San Jose, CA, USA). The plates were
incubated quiescently at 37 ◦C for 10 min to allow the reactions to equilibrate, then an initial
reading was taken. Plates were incubated at 37 ◦C on an orbital plate shaker operating at
1000 rpm. Further readings were taken at regular intervals.
Once aggregation had completed (determined by a plateau in the ThT fluorescence) in
all wells without added small molecule, a final fluorescence measurement was taken. The
plate was then unsealed and a 1 µL bolus of small molecule solution was added to each
of the 3 control wells. Fluorescence was measured again to determine the effect of small
molecule on ThT fluorescence. The change in fluorescence upon small-molecule addition
was defined as the difference in fluorescence in each control well, corrected for the average
change in the wells which had initially contained the same small molecule, which had
not otherwise been manipulated between readings, to account for evaporation or other
changes during handling.
4.4. Filter Trap Assay
Samples were drawn through a cellulose acetate membrane (Sterilitech, Kent, WA,
USA) and cellulose nitrate membrane (Bio-Rad, Hercules, CA, USA) using a Bio-Dot
vacuum manifold (Bio-Rad). The membranes were pre-wetted with PBS, then 100 µL of
sample was drawn through. The protein spots were washed 3 times by drawing 200 µL
PBS through the membranes. Membranes were stained with 0.1% (w/v) amido black in
10% (v/v) acetic acid, then gently washed with 5% acetic acid and deionized water until the
background stain was removed. Aggregated protein adheres weakly to cellulose acetate
and can be knocked off by vigorous washing. Spots were imaged using an ImageQuant
LAS 4000 gel imaging system (Cytiva) and quantitated with ImageLab software (Bio-
Rad), treating each spot as a gel band in order to control the software’s background
subtraction feature. The ratios between the background-corrected intensities are reported
in Figures 5 and 6 without further normalization.
4.5. Fibril Dissociation
A single batch of 6aJL2-VL fibrils was prepared by incubating 5 µM VL-domain in PBS
at 37 ◦C, 200 rpm, until visible aggregates formed. Fibrils were vortexed, then split into
500 µL aliquots and centrifuged at 20,000× g for 10 min. The supernatant was aspirated
to remove any remaining soluble LC, leaving 10 µL in the tubes to avoid disturbing the
pelleted fibrils. The fibrils were resuspended in PBS containing 50 µM of small molecule
and vortexed. Four samples per molecule were incubated quiescently at 37 ◦C for seven or
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fifteen days (2 samples each). The fifteen-day incubation was chosen to replicate similar
experiments, where doxycycline was observed to dissociate fibrils [22]. After incubation,
samples were centrifuged at 20,000× g for 10 min to separate soluble LC from fibrils. The
pellets were resuspended in PBS without small molecules and both samples were stored
at 4 ◦C until soluble and insoluble fractions were measured by the filter trap assay, which
was carried out as described above. A total of 80 samples was used for the filter trap
assay: two replicates each of supernatant and precipitate, at two timepoints, for ten small
molecules, including ethanol and water vehicles. This experimental design precluded
triplicate experiments, so that all samples could be stained on the same membranes.
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